Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers

2020 ◽  
Vol 49 (15) ◽  
pp. 5446-5472 ◽  
Author(s):  
Kayoung Kim ◽  
Chang Heon Lee ◽  
Chan Beum Park
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Chemical Sensing ◽  
Electrical Detection ◽  
Trace Level ◽  
Disease Biomarkers ◽  
Recent Advances ◽  
Sensing Platforms

This review provides an overview of recent advances in optical and electrical detection of Alzheimer's disease biomarkers in clinically relevant fluids.

scholarly journals Association of CSF Alzheimer's disease biomarkers with postoperative delirium in older adults

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Tamara G. Fong ◽  
Sarinnapha M. Vasunilashorn ◽  
Yun Gou ◽  
Towia A. Libermann ◽  
Simon Dillon ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Older Adults ◽  
Alzheimer's Disease ◽  
Postoperative Delirium ◽  
Disease Biomarkers

scholarly journals Correlation between oligomerizaton of amyloid beta in plasma and other Alzheimer's disease biomarkers

IBRO Reports ◽  
2019 ◽  
Vol 6 ◽  
pp. S91
Author(s):  
Sungmin Kang ◽  
Jeewon Suh ◽  
Jeong Min Pyun ◽  
Young Chul Youn ◽  
Ji Sun Yu ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Amyloid Beta ◽  
Disease Biomarkers

scholarly journals Pre‐analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF

2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Oskar Hansson ◽  
Sandra Rutz ◽  
Henrik Zetterberg ◽  
Ekaterina Bauer ◽  
Teresa Hähl ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Biomarkers ◽  
Analytical Protocol

scholarly journals Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid‐life: A randomized trial

2021 ◽  
Author(s):  
Siobhan Hoscheidt ◽  
Ashley H. Sanderlin ◽  
Laura D. Baker ◽  
Youngkyoo Jung ◽  
Samuel Lockhart ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Randomized Trial ◽  
Cerebral Perfusion ◽  
Western Diet ◽  
Disease Biomarkers

Recent advances in pre-clinical diagnosis of Alzheimer’s disease

2021 ◽  
Author(s):  
John Zhou ◽  
Marc Benoit ◽  
Md Golam Sharoar
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Diagnosis ◽  
Recent Advances

Clinical Characteristic in Primary Progressive Aphasia in Relation to Alzheimer’s Disease Biomarkers

2021 ◽  
pp. 1-13
Author(s):  
Sung Hoon Kang ◽  
Hanna Cho ◽  
Jiho Shin ◽  
Hang-Rai Kim ◽  
Young Noh ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Language Impairment ◽  
Amyloid Β ◽  
Primary Progressive Aphasia ◽  
Cortical Atrophy ◽  
Clinical Feature ◽  
Progressive Aphasia ◽  
Disease Biomarkers ◽  
Primary Progressive

Background: Primary progressive aphasia (PPA) is associated with amyloid-β (Aβ) pathology. However, clinical feature of PPA based on Aβ positivity remains unclear. Objective: We aimed to assess the prevalence of Aβ positivity in patients with PPA and compare the clinical characteristics of patients with Aβ-positive (A+) and Aβ-negative (A–) PPA. Further, we applied Aβ and tau classification system (AT system) in patients with PPA for whom additional information of in vivo tau biomarker was available. Methods: We recruited 110 patients with PPA (41 semantic [svPPA], 27 non-fluent [nfvPPA], 32 logopenic [lvPPA], and 10 unclassified [ucPPA]) who underwent Aβ-PET imaging at multi centers. The extent of language impairment and cortical atrophy were compared between the A+ and A–PPA subgroups using general linear models. Results: The prevalence of Aβ positivity was highest in patients with lvPPA (81.3%), followed by ucPPA (60.0%), nfvPPA (18.5%), and svPPA (9.8%). The A+ PPA subgroup manifested cortical atrophy mainly in the left superior temporal/inferior parietal regions and had lower repetition scores compared to the A–PPA subgroup. Further, we observed that more than 90%(13/14) of the patients with A+ PPA had tau deposition. Conclusion: Our findings will help clinicians understand the patterns of language impairment and cortical atrophy in patients with PPA based on Aβ deposition. Considering that most of the A+ PPA patents are tau positive, understanding the influence of Alzheimer’s disease biomarkers on PPA might provide an opportunity for these patients to participate in clinical trials aimed for treating atypical Alzheimer’s disease.

scholarly journals Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project

2018 ◽  
Vol 10 (1) ◽  
pp. 563-572 ◽  
Author(s):  
Eline A.J. Willemse ◽  
Ingrid S. Maurik ◽  
Betty M. Tijms ◽  
Femke H. Bouwman ◽  
Andreas Franke ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Diagnostic Performance ◽  
Memory Clinic ◽  
Disease Biomarkers

scholarly journals Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease

2018 ◽  
Vol 4 (1) ◽  
pp. 669-676 ◽  
Author(s):  
Guoqiao Wang ◽  
Chengjie Xiong ◽  
Eric M. McDade ◽  
Jason Hassenstab ◽  
Andrew J. Aschenbrenner ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Longitudinal Changes ◽  
Disease Biomarkers ◽  
Baseline Levels
Sign in / Sign up

Export Citation Format

Share Document